{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T22:38:02Z","timestamp":1775083082506,"version":"3.50.1"},"reference-count":67,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,7]],"date-time":"2025-12-07T00:00:00Z","timestamp":1765065600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007435","name":"Ake Wiberg Stiftelse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007435","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006313","name":"Childhood Cancer Foundation","doi-asserted-by":"publisher","award":["TJ2021-0111"],"award-info":[{"award-number":["TJ2021-0111"]}],"id":[{"id":"10.13039\/501100006313","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002794","name":"Swedish Cancer Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009252","name":"Science for Life Laboratory","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009252","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016408","name":"Goran Gustafsson's Foundations","doi-asserted-by":"publisher","award":["2024-2445"],"award-info":[{"award-number":["2024-2445"]}],"id":[{"id":"10.13039\/100016408","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004047","name":"Karolinska Institutet","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007051","name":"Uppsala Universitet","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007051","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007678","name":"Center for Modelling and Simulation in the Biosciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007678","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.bcp.2025.117625","type":"journal-article","created":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T16:01:09Z","timestamp":1765036869000},"page":"117625","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Albacarcin V adds EPLIN as a novel and promising target for the treatment of female cancers and pediatric medulloblastoma"],"prefix":"10.1016","volume":"244","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-8024-3901","authenticated-orcid":false,"given":"Lucia","family":"Krahulcov\u00e1","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emma","family":"Lindell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1650-9974","authenticated-orcid":false,"given":"Xi","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica Javiera","family":"Conejeros Monsalve","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0743-7830","authenticated-orcid":false,"given":"Martin","family":"Haraldsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-1034-017X","authenticated-orcid":false,"given":"Zhixiong","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinsong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guro","family":"Aune","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4895-1177","authenticated-orcid":false,"given":"Miao","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5298-8255","authenticated-orcid":false,"given":"Le","family":"Tong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johan","family":"Hartman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaisa","family":"Lehti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8460-4367","authenticated-orcid":false,"given":"Fredrik Johansson","family":"Swartling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5657-2839","authenticated-orcid":false,"given":"Xingqi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6668-4140","authenticated-orcid":false,"given":"Tobias","family":"Sj\u00f6blom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4359-9079","authenticated-orcid":false,"given":"Xiaonan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2025.117625_b0005","unstructured":"Cancer (IARC) TIA for R on. Global Cancer Observatory. Accessed April 22, 2024. https:\/\/gco.iarc.fr\/."},{"issue":"3","key":"10.1016\/j.bcp.2025.117625_b0010","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.3390\/ijms25031845","article-title":"Paradigm shift: a comprehensive review of ovarian cancer management in an era of advancements","volume":"25","author":"Tavares","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.bcp.2025.117625_b0015","doi-asserted-by":"crossref","first-page":"82","DOI":"10.3892\/or.2022.8293","article-title":"Molecular mechanisms of platinum\u2011based chemotherapy resistance in ovarian cancer (Review)","volume":"47","author":"Yang","year":"2022","journal-title":"Oncol. Rep."},{"issue":"9","key":"10.1016\/j.bcp.2025.117625_b0020","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1158\/1541-7786.MCR-23-0680","article-title":"Crizotinib enhances PARP inhibitor efficacy in ovarian cancer cells and xenograft models by inducing autophagy","volume":"22","author":"Santiago-O\u2019Farrill","year":"2024","journal-title":"Mol. Cancer Res."},{"issue":"5","key":"10.1016\/j.bcp.2025.117625_b0025","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/s41417-024-00748-w","article-title":"Dual-inhibition of NAMPT and PAK4 induces anti-tumor effects in 3D-spheroids model of platinum-resistant ovarian cancer","volume":"31","author":"Kudo","year":"2024","journal-title":"Cancer Gene Ther."},{"issue":"2","key":"10.1016\/j.bcp.2025.117625_b0030","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1002\/jcp.29913","article-title":"Osthole interacts with an ER\u2010mitochondria axis and facilitates tumor suppression in ovarian cancer","volume":"236","author":"Bae","year":"2021","journal-title":"J. Cell. Physiol."},{"issue":"5","key":"10.1016\/j.bcp.2025.117625_b0035","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S1470-2045(21)00073-5","article-title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"22","author":"Poveda","year":"2021","journal-title":"Lancet Oncol."},{"issue":"3","key":"10.1016\/j.bcp.2025.117625_b0040","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1200\/JCO.22.01549","article-title":"Overall survival with maintenance Olaparib at a 7-year follow-up in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: the SOLO1\/GOG 3004 trial","volume":"41","author":"DiSilvestro","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bcp.2025.117625_b0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.04.024","article-title":"Progression-free survival and safety at 3.5 years of follow-up: results from the randomised phase 3 PRIMA\/ENGOT-OV26\/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer","volume":"189","author":"Gonz\u00e1lez-Mart\u00edn","year":"2023","journal-title":"Eur. J. Cancer"},{"issue":"34","key":"10.1016\/j.bcp.2025.117625_b0050","doi-asserted-by":"crossref","first-page":"3965","DOI":"10.1200\/JCO.22.01207","article-title":"Identification of patients with ovarian cancer experiencing the highest benefit from bevacizumab in the first-line setting on the basis of their tumor-intrinsic chemosensitivity (KELIM): the GOG-0218 validation study","volume":"40","author":"You","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.bcp.2025.117625_b0055","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1136\/ijgc-2024-005401","article-title":"Mirvetuximab soravtansine in folate receptor alpha (FR\u03b1)\u2013high platinum-resistant ovarian cancer: final overall survival and post hoc sequence of therapy subgroup results from the SORAYA trial","volume":"34","author":"Coleman","year":"2024","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.bcp.2025.117625_b0060","unstructured":"Lynparza | European Medicines Agency (EMA). January 9, 2015. Accessed January 26, 2025. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/lynparza."},{"key":"10.1016\/j.bcp.2025.117625_b0065","unstructured":"Elahere | European Medicines Agency (EMA). December 10, 2024. Accessed February 8, 2025. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/elahere."},{"key":"10.1016\/j.bcp.2025.117625_b0070","unstructured":"Vegzelma | European Medicines Agency (EMA). September 7, 2022. Accessed February 8, 2025. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/vegzelma."},{"issue":"1","key":"10.1016\/j.bcp.2025.117625_b0075","doi-asserted-by":"crossref","first-page":"9873","DOI":"10.1038\/s41598-021-87968-4","article-title":"Edelfosine nanoemulsions inhibit tumor growth of triple negative breast cancer in zebrafish xenograft model","volume":"11","author":"Saraiva","year":"2021","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.bcp.2025.117625_b0080","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1186\/s12967-024-05692-9","article-title":"Identification of the metabolic protein ATP5MF as a potential therapeutic target of TNBC","volume":"22","author":"Chen","year":"2024","journal-title":"J. Transl. Med."},{"issue":"6","key":"10.1016\/j.bcp.2025.117625_b0085","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.3892\/ijo.2020.5135","article-title":"Triple\u2011negative breast cancer therapy: current and future perspectives (Review)","volume":"57","author":"Won","year":"2020","journal-title":"Int. J. Oncol."},{"issue":"1","key":"10.1016\/j.bcp.2025.117625_b0090","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s13046-021-01930-w","article-title":"Efficacy and mechanism of the combination of PARP and CDK4\/6 inhibitors in the treatment of triple-negative breast cancer","volume":"40","author":"Zhu","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.bcp.2025.117625_b0095","unstructured":"Keytruda | European Medicines Agency (EMA). July 30, 2015. Accessed January 26, 2025."},{"key":"10.1016\/j.bcp.2025.117625_b0100","unstructured":"Trodelvy | European Medicines Agency (EMA). November 24, 2021. Accessed January 26, 2025."},{"key":"10.1016\/j.bcp.2025.117625_b0105","unstructured":"Tecentriq | European Medicines Agency (EMA). September 29, 2017. Accessed January 26, 2025."},{"issue":"6","key":"10.1016\/j.bcp.2025.117625_b0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.102043","article-title":"Multidisciplinary clinical guidelines in proactive monitoring, early diagnosis, and effective management of trastuzumab deruxtecan (T-DXd)-induced interstitial lung disease (ILD) in breast cancer patients","volume":"8","author":"Wekking","year":"2023","journal-title":"ESMO Open"},{"issue":"10","key":"10.1016\/j.bcp.2025.117625_b0115","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.annonc.2023.07.003","article-title":"Trastuzumab deruxtecan (T-DXd) in HER2-low metastatic breast cancer treatment","volume":"34","author":"Tarantino","year":"2023","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.bcp.2025.117625_b0120","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s10549-024-07333-7","article-title":"Long-term outcomes of neoadjuvant trastuzumab emtansine + pertuzumab (T-DM1 + P) and docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP) for HER2-positive primary breast cancer: results of the randomized phase 2 JBCRG20 study (Neo-peaks)","volume":"207","author":"Takano","year":"2024","journal-title":"Breast Cancer Res. Treat."},{"issue":"1","key":"10.1016\/j.bcp.2025.117625_b0125","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.1038\/s41467-020-16170-3","article-title":"Acquired resistance to combined BET and CDK4\/6 inhibition in triple-negative breast cancer","volume":"11","author":"Ge","year":"2020","journal-title":"Nat. Commun."},{"issue":"5","key":"10.1016\/j.bcp.2025.117625_b0130","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1007\/s00210-022-02375-4","article-title":"Novel combination treatment of CDK 4\/6 inhibitors with PARP inhibitors in triple negative breast cancer cells","volume":"396","author":"Guney Eskiler","year":"2023","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"issue":"7","key":"10.1016\/j.bcp.2025.117625_b0135","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.7150\/ijbs.91861","article-title":"Paris saponin VII reverses resistance to PARP inhibitors by regulating ovarian cancer tumor angiogenesis and glycolysis through the ROR\u03b1\/ECM1\/VEGFR2 signaling axis","volume":"20","author":"Wang","year":"2024","journal-title":"Int. J. Biol. Sci."},{"issue":"1","key":"10.1016\/j.bcp.2025.117625_b0140","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s12943-024-02025-8","article-title":"PARP1-DOT1L transcription axis drives acquired resistance to PARP inhibitor in ovarian cancer","volume":"23","author":"Liu","year":"2024","journal-title":"Mol. Cancer"},{"issue":"4","key":"10.1016\/j.bcp.2025.117625_b0145","doi-asserted-by":"crossref","first-page":"3762","DOI":"10.3390\/ijms24043762","article-title":"Quiescent cancer cells\u2014a potential therapeutic target to overcome tumor resistance and relapse","volume":"24","author":"Lindell","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"11","key":"10.1016\/j.bcp.2025.117625_b0150","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.trecan.2016.10.009","article-title":"Eradicating quiescent tumor cells by targeting mitochondrial bioenergetics","volume":"2","author":"Zhang","year":"2016","journal-title":"Trends Cancer"},{"issue":"1","key":"10.1016\/j.bcp.2025.117625_b0155","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s13058-017-0877-7","article-title":"AKT1(low) quiescent cancer cells persist after neoadjuvant chemotherapy in triple negative breast cancer","volume":"19","author":"Kabraji","year":"2017","journal-title":"Breast Cancer Res."},{"issue":"7","key":"10.1016\/j.bcp.2025.117625_b0160","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.131486","article-title":"NFATC4 promotes quiescence and chemotherapy resistance in ovarian cancer","volume":"5","author":"Cole","year":"2020","journal-title":"JCI Insight"},{"issue":"1","key":"10.1016\/j.bcp.2025.117625_b0165","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1038\/s41419-025-07876-7","article-title":"Identification of a small molecule targeting EPLIN as a novel strategy for the treatment of pediatric neuroblastoma and medulloblastoma","volume":"16","author":"Lindell","year":"2025","journal-title":"Cell Death Dis."},{"issue":"10","key":"10.1016\/j.bcp.2025.117625_b0170","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/s41419-023-06204-1","article-title":"Identification of ATF3 as a novel protective signature of quiescent colorectal tumor cells","volume":"14","author":"Lu","year":"2023","journal-title":"Cell Death Dis."},{"issue":"1","key":"10.1016\/j.bcp.2025.117625_b0175","doi-asserted-by":"crossref","first-page":"4590","DOI":"10.1038\/s41467-018-07115-y","article-title":"Joint single-cell DNA accessibility and protein epitope profiling reveals environmental regulation of epigenomic heterogeneity","volume":"9","author":"Chen","year":"2018","journal-title":"Nat. Commun."},{"issue":"12","key":"10.1016\/j.bcp.2025.117625_b0180","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1038\/nmeth.2688","article-title":"Transposition of native chromatin for fast and sensitive epigenomic profiling of open chromatin, DNA-binding proteins and nucleosome position","volume":"10","author":"Buenrostro","year":"2013","journal-title":"Nat. Methods"},{"issue":"3","key":"10.1016\/j.bcp.2025.117625_b0185","doi-asserted-by":"crossref","first-page":"R25","DOI":"10.1186\/gb-2009-10-3-r25","article-title":"Ultrafast and memory-efficient alignment of short DNA sequences to the human genome","volume":"10","author":"Langmead","year":"2009","journal-title":"Genome Biol."},{"issue":"4","key":"10.1016\/j.bcp.2025.117625_b0190","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.molcel.2010.05.004","article-title":"Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities","volume":"38","author":"Heinz","year":"2010","journal-title":"Mol. Cell"},{"issue":"1","key":"10.1016\/j.bcp.2025.117625_b0195","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/nbt.1754","article-title":"Integrative genomics viewer","volume":"29","author":"Robinson","year":"2011","journal-title":"Nat. Biotechnol."},{"issue":"9","key":"10.1016\/j.bcp.2025.117625_b0200","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1038\/nprot.2014.138","article-title":"The cellular thermal shift assay for evaluating drug target interactions in cells","volume":"9","author":"Jafari","year":"2014","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.bcp.2025.117625_b0205","first-page":"1","article-title":"Evidence for the existence of triple-negative variants in the MCF-7 breast cancer cell population","volume":"2014","author":"Leung","year":"2014","journal-title":"Biomed Res. Int."},{"issue":"1","key":"10.1016\/j.bcp.2025.117625_b0210","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.1038\/ncomms4295","article-title":"Induction of mitochondrial dysfunction as a strategy for targeting tumour cells in metabolically compromised microenvironments","volume":"5","author":"Zhang","year":"2014","journal-title":"Nat. Commun."},{"issue":"6","key":"10.1016\/j.bcp.2025.117625_b0215","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1158\/1535-7163.MCT-14-0792","article-title":"Three-dimensional cell culture-based screening identifies the anthelmintic drug nitazoxanide as a candidate for treatment of colorectal cancer","volume":"14","author":"Senkowski","year":"2015","journal-title":"Mol. Cancer Ther."},{"issue":"7472","key":"10.1016\/j.bcp.2025.117625_b0220","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/nature12751","article-title":"Chromatin proteins and modifications as drug targets","volume":"502","author":"Helin","year":"2013","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.bcp.2025.117625_b0225","doi-asserted-by":"crossref","first-page":"6629","DOI":"10.1038\/s41467-025-61769-z","article-title":"Deciphering direct transcriptional effects of epigenetic compounds through large-scale new RNA profiling","volume":"16","author":"Hartmanis","year":"2025","journal-title":"Nat. Commun."},{"issue":"34","key":"10.1016\/j.bcp.2025.117625_b0230","doi-asserted-by":"crossref","first-page":"54488","DOI":"10.18632\/oncotarget.10239","article-title":"Prognostic significance of PLIN1 expression in human breast cancer","volume":"7","author":"Zhou","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.bcp.2025.117625_b0235","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/1476-4598-7-71","article-title":"Eplin-alpha expression in human breast cancer, the impact on cellular migration and clinical outcome","volume":"7","author":"Jiang","year":"2008","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.bcp.2025.117625_bib326","doi-asserted-by":"crossref","DOI":"10.1111\/bph.70215","article-title":"Pathway-level mutational signatures predict breast cancer outcomes and reveal therapeutic targets","author":"Posta","year":"2025","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.bcp.2025.117625_bib327","doi-asserted-by":"crossref","DOI":"10.1007\/s11357-023-00742-4","article-title":"Discovery and ranking of the most robust prognostic biomarkers in serous ovarian cancer","author":"Gyorffy","year":"2023","journal-title":"Geroscience"},{"issue":"1","key":"10.1016\/j.bcp.2025.117625_b0240","doi-asserted-by":"crossref","first-page":"3459","DOI":"10.1038\/s41598-017-03811-9","article-title":"Reduction in migratory phenotype in a metastasized breast cancer cell line via downregulation of S100A4 and GRM3","volume":"7","author":"Chen","year":"2017","journal-title":"Sci. Rep."},{"issue":"5","key":"10.1016\/j.bcp.2025.117625_b0245","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0178174","article-title":"The human asparaginase enzyme (ASPG) inhibits growth in leukemic cells","volume":"12","author":"Belviso","year":"2017","journal-title":"PLoS One"},{"issue":"Pt 7","key":"10.1016\/j.bcp.2025.117625_b0250","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1242\/jcs.094300","article-title":"The myosin superfamily at a glance","volume":"125","author":"Hartman","year":"2012","journal-title":"J. Cell Sci."},{"issue":"9","key":"10.1016\/j.bcp.2025.117625_b0255","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25094970","article-title":"Exploring the enigma: the role of the epithelial protein lost in neoplasm in normal physiology and cancer pathogenesis","volume":"25","author":"Lindell","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"6393","key":"10.1016\/j.bcp.2025.117625_b0260","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1126\/science.aao6575","article-title":"A LIMA1 variant promotes low plasma LDL cholesterol and decreases intestinal cholesterol absorption","volume":"360","author":"Zhang","year":"2018","journal-title":"Science"},{"issue":"54","key":"10.1016\/j.bcp.2025.117625_b0265","doi-asserted-by":"crossref","first-page":"7838","DOI":"10.1038\/sj.onc.1203206","article-title":"EPLIN, epithelial protein lost in neoplasm","volume":"18","author":"Maul","year":"1999","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.bcp.2025.117625_b0270","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41392-022-01285-4","article-title":"Ribosome biogenesis in disease: new players and therapeutic targets","volume":"8","author":"Jiao","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"issue":"15","key":"10.1016\/j.bcp.2025.117625_b0275","doi-asserted-by":"crossref","first-page":"3903","DOI":"10.1158\/1078-0432.CCR-15-3011","article-title":"DiSCoVERing innovative therapies for rare tumors: combining genetically accurate disease models with in silico analysis to identify novel therapeutic targets","volume":"22","author":"Hanaford","year":"2016","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.bcp.2025.117625_b0280","doi-asserted-by":"crossref","first-page":"8726","DOI":"10.1038\/s41598-019-45278-w","article-title":"A Selective FGFR inhibitor AZD4547 suppresses RANKL\/M-CSF\/OPG-dependent ostoclastogenesis and breast cancer growth in the metastatic bone microenvironment","volume":"9","author":"Kang","year":"2019","journal-title":"Sci. Rep."},{"issue":"51","key":"10.1016\/j.bcp.2025.117625_b0285","doi-asserted-by":"crossref","first-page":"16821","DOI":"10.1021\/bi00051a033","article-title":"Differential effects of ethyl 5-amino-2-methyl-1,2-dihydro-3-phenylpyrido[3,4-b]pyrazin-7-yl carbamate analogs modified at position C2 on tubulin polymerization, binding, and conformational changes","volume":"34","author":"Barbier","year":"1995","journal-title":"Biochemistry"},{"issue":"24","key":"10.1016\/j.bcp.2025.117625_b0290","doi-asserted-by":"crossref","first-page":"4586","DOI":"10.1158\/0008-5472.CAN-22-2108","article-title":"Dormant SOX9-positive cells facilitate MYC-driven recurrence of medulloblastoma","volume":"82","author":"Borgenvik","year":"2022","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.bcp.2025.117625_b0295","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1038\/s41467-023-36847-9","article-title":"ARF suppression by MYC but not MYCN confers increased malignancy of aggressive pediatric brain tumors","volume":"14","author":"Mainwaring","year":"2023","journal-title":"Nat. Commun."},{"issue":"10","key":"10.1016\/j.bcp.2025.117625_b0300","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1101\/gad.1907510","article-title":"Pleiotropic role for MYCN in medulloblastoma","volume":"24","author":"Swartling","year":"2010","journal-title":"Genes Dev."},{"issue":"1","key":"10.1016\/j.bcp.2025.117625_b0305","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s12866-024-03258-9","article-title":"Optimization of fermentation conditions and medium components for chrysomycin a production by Streptomyces sp. 891-B6","volume":"24","author":"Hu","year":"2024","journal-title":"BMC Microbiol."},{"issue":"14","key":"10.1016\/j.bcp.2025.117625_b0310","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1016\/0959-8049(93)90459-S","article-title":"Biochemical characterisation of elsamicin and other coumarin-related antitumour agents as potent inhibitors of human topoisomerase II","volume":"29A","author":"Lorico","year":"1993","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.bcp.2025.117625_b0315","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106565","article-title":"Upgrade of chrysomycin a as a novel topoisomerase II inhibitor to curb KRAS-mutant lung adenocarcinoma progression","volume":"187","author":"Zhang","year":"2023","journal-title":"Pharmacol. Res."},{"issue":"19","key":"10.1016\/j.bcp.2025.117625_b0320","doi-asserted-by":"crossref","DOI":"10.3390\/molecules27196148","article-title":"Chrysomycin a inhibits the proliferation, migration and invasion of U251 and U87-MG glioblastoma cells to exert its anti-cancer effects","volume":"27","author":"Liu","year":"2022","journal-title":"Molecules"},{"issue":"13","key":"10.1016\/j.bcp.2025.117625_b0325","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22136799","article-title":"Chrysomycin a attenuates neuroinflammation by down-regulating NLRP3\/cleaved caspase-1 signaling pathway in LPS-stimulated mice and BV2 cells","volume":"22","author":"Liu","year":"2021","journal-title":"Int. J. Mol. Sci."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295225008901?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295225008901?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T01:00:08Z","timestamp":1773882008000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295225008901"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":67,"alternative-id":["S0006295225008901"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2025.117625","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Albacarcin V adds EPLIN as a novel and promising target for the treatment of female cancers and pediatric medulloblastoma","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2025.117625","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"117625"}}